RESUMO
In the last several years, the use of dendritic cells has been studied as a therapeutic strategy against tumors. Dendritic cells can be pulsed with peptides or full-length protein, or they can be transfected with DNA or RNA. However, comparative studies suggest that transfecting dendritic cells with messenger RNA (mRNA) is superior to other antigen-loading techniques in generating immunocompetent dendritic cells. In the present study, we evaluated a new therapeutic strategy to fight tuberculosis using dendritic cells and macrophages transfected with Hsp65 mRNA. First, we demonstrated that antigen-presenting cells transfected with Hsp65 mRNA exhibit a higher level of expression of co-stimulatory molecules, suggesting that Hsp65 mRNA has immunostimulatory properties. We also demonstrated that spleen cells obtained from animals immunized with mock and Hsp65 mRNA-transfected dendritic cells were able to generate a mixed Th1/Th2 response with production not only of IFN-γ but also of IL-5 and IL-10. In contrast, cells recovered from mice immunized with Hsp65 mRNA-transfected macrophages were able to produce only IL-5. When mice were infected with Mycobacterium tuberculosis and treated with antigen-presenting cells transfected with Hsp65 mRNA (therapeutic immunization), we did not detect any decrease in the lung bacterial load or any preservation of the lung parenchyma, indicating the inability of transfected cells to confer curative effects against tuberculosis. In spite of the lack of therapeutic efficacy, this study reports for the first time the use of antigen-presenting cells transfected with mRNA in experimental tuberculosis.
Assuntos
Células Apresentadoras de Antígenos/imunologia , Proteínas de Bactérias/administração & dosagem , Chaperonina 60/administração & dosagem , Mycobacterium tuberculosis/imunologia , RNA Mensageiro/imunologia , Vacinas contra a Tuberculose/administração & dosagem , Tuberculose/imunologia , Animais , Proteínas de Bactérias/efeitos adversos , Proteínas de Bactérias/imunologia , Chaperonina 60/efeitos adversos , Chaperonina 60/imunologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , RNA Mensageiro/efeitos adversos , Baço/imunologia , Transfecção , Tuberculose/prevenção & controle , Vacinas contra a Tuberculose/efeitos adversos , Vacinas contra a Tuberculose/imunologiaRESUMO
IMPORTANCE OF THE FIELD: Type 1 diabetes is a chronic autoimmune disease in which pancreatic beta cells are selectively destroyed. Ultimately hyperglycemia develops and insulin substitution becomes necessary. Immunomodulation aims at arresting this autoimmune attack. DiaPep277, the major T-cell epitope of heat shock protein 60 (hsp60), has been shown to be effective as a modulator of the immune system in type 1 diabetes and is the focus of this review. AREAS COVERED IN THIS REVIEW: A literature search of Pubmed listed publications covering 1990 - 2009 and a website search of the licensing company were performed. WHAT THE READER WILL GAIN: DiaPep277 has been successfully employed in animal models and has been investigated in Phase I - III studies in humans. A combined analysis of the Phase II trials showed a significant preservation of beta cell function in adults without adverse effects, but HbA1c was not changed. A Phase III clinical trial is ongoing, and a second Phase III trial will start in early 2010. Addressing the underlying autoimmune process is the call of the future in type 1 diabetes. TAKE HOME MESSAGE: Use of Diapep277 is a promising therapeutic strategy currently being tested in Phase III trials.
Assuntos
Chaperonina 60/uso terapêutico , Diabetes Mellitus Tipo 1/tratamento farmacológico , Fatores Imunológicos/uso terapêutico , Células Secretoras de Insulina/efeitos dos fármacos , Fragmentos de Peptídeos/uso terapêutico , Animais , Chaperonina 60/efeitos adversos , Ensaios Clínicos Fase I como Assunto , Ensaios Clínicos Fase II como Assunto , Ensaios Clínicos Fase III como Assunto , Diabetes Mellitus Tipo 1/fisiopatologia , Humanos , Imunidade Inata/efeitos dos fármacos , Fatores Imunológicos/efeitos adversos , Fragmentos de Peptídeos/efeitos adversos , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologia , VacinaçãoRESUMO
The expression of heat shock proteins HSP60 and HSP70 and cytokeratins CK1/10 and CK7/18 were compared in epithelium of oral lichen planus (OLP) lesions and oral fibromas using an avidin-biotin-peroxidase complex (ABC) immunohistochemical method. An immunostaining intensity distribution (IID) index was developed to assess staining intensity and the proportion of positively stained cells in different layers of the epithelium. The expression of HSP60 in the basal layer was significantly higher in OLP than in fibromas. No difference in HSP70 expression was evident between OLP and fibromas. The expression of CK1/10 in the epithelial basal and suprabasal layers was significantly higher in OLP than in fibromas. There was no demonstrable staining for CK7/18 in either OLP or fibromas. A significant correlation was evident between the expression of HSP60 and CK1/10 in the basal epithelial cells in OLP. The findings support a role for HSP60 in the pathogenesis of OLP. A unifying hypothesis of the pathogenesis of OLP, involving two sequential immune reactions, is proposed.